Communiqués Celcuity Inc.

Actions

CELC

US15102K1007

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
86,38 ^USD	-1,44%		+4,55%	-13,39%

30/07	Celcuity annonce l'approbation de la FDA et l'inclusion dans les directives du NCCN pour REVTORPYK en association avec le fulvestrant, avec ou sans palbociclib	CI
15/07	Transcript : Celcuity Inc. - Special Call

Communiqués

30/07	Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer	AQ
14/07	Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	AQ
04/06	Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032	AQ
03/06	Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032	AQ
02/06	Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer	AQ
01/06	Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026	AQ
28/05	Celcuity To Participate in Upcoming Investor Conferences	AQ
14/05	Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update	AQ
14/05	Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients	AQ
07/05	Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call	AQ
01/05	Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort	AQ
25/03	Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
18/03	Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call	AQ
10/03	Celcuity : VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer	PU
09/03	Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology	AQ
25/02	Celcuity To Participate in Upcoming Investor Conferences	AQ
12/02	Celcuity Appoints Charles Romp to its Board of Directors	AQ
04/02	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
20/01	Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer	AQ
11/12	Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium	AQ
11/12	Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, plus fulvestrant with or without palbociclib for second-line treatment of patients with HR+/HER2-/ PIK3CA-WT advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial	PU
26/11	Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium	AQ
26/11	Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference	AQ
17/11	Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer	AQ
13/11	Celcuity : Corporate Presentation (Celcuity Investor Presentation V.7.1.3 Final)	PU